News

Press Releases

April 16, 2025

Oral presentation will feature AI-081, a potentially best-in-class PD-1/VEGF bispecific antibody and ONC-841, a first-in-class anti-Siglec-10 antibody Initial Phase 1 […]

Read more
December 2, 2024

ROCKVILLE, Maryland, December 2, 2024 (GLOBE NEWSWIRE) –– OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer and neurological […]

Read more
October 1, 2024

Our merger announcement of OncoC4 with AcroImmune has generated great excitement from multiple major news outlets, and here are some […]

Read more
September 25, 2024

ROCKVILLE, Maryland, September 25, 2024 (GLOBE NEWSWIRE) – OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, and […]

Read more
August 30, 2024

ROCKVILLE, Maryland, USA, August 30, 2024 — OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer and […]

Read more
Scroll to Top